Table 3.
Demographic and clinical characteristics of ADHD subjects according to genotypes of the -3081(A/T) polymorphism
| ADHD subjects with A/A genotype |
ADHD subjects with A/T + T/T genotypes |
p-value | |
|---|---|---|---|
| Age in yr, mean (SD) | 9.0 (2.4) | 9.1 (2.0) | 0.81 |
| Sex (M/F) | 22/7 | 70/13 | 0.31 |
| IQ, mean (SD) | 107.2 (13.3) | 107.5 (14.0) | 0.92 |
| ADHD subtypes | 0.35 | ||
| Combined | 58.6% | 62.7% | |
| Inattentive | 34.5% | 22.9% | |
| Hyperactive-impulsive | 0.0% | 7.2% | |
| NOS | 6.9% | 7.2% | |
| Comorbidity | |||
| Oppositional defiant disorder | 6.9% | 15.7% | 0.19 |
| Anxiety disorder | 3.4% | 13.3% | 0.13 |
| Enuresis | 13.8% | 1.2% | 0.02 |
| ARS baseline scores, mean (SD) | |||
| Total | 23.9 (11.4) | 27.9 (9.7) | 0.08 |
| Inattentive | 13.6 (6.3) | 15.6 (5.6) | 0.12 |
| Hyperactivity/impulsivity | 10.3 (6.9) | 12.3 (5.7) | 0.14 |
| Dosage of MPH (mg/day), mean (SD) | |||
| Baseline dose | 19.7 (9.3) | 20.0 (8.0) | 0.88 |
| Final 2 weeks dose | 27.9 (11.1) | 29.7 (11.8) | 0.48 |
| CGI-I score, mean (SD) | 2.8 (0.9) | 2.4 (0.8) | 0.04 |
ADHD, Attention-Deficit/Hyperactivity Disorder; NOS, Not Otherwise Specified; ARS, ADHD Rating Scale; MPH, Methylphenidate